Epithelix (www.epithelix.com) is a pioneering biotechnology company specializing in tissue engineering and in vitro respiratory disease modelling. Founded in 2006, the company is headquartered in Plan-les-Ouates, Geneva, Switzerland. Epithelix is a pioneer and leader in the in vitro evaluation of drug efficacy and toxicity on human airways.
The company has developed unique 3D human airway tissue models and testing services to study respiratory diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD), as well as bacterial and viral infections and inhalation toxicity.
The MucilAir™, SmallAir™, and AlveolAir™ models developed by Epithelix are marketed in Europe, North America, and Asia to major pharmaceutical, cosmetic, and chemical industry players, as well as numerous public research laboratories. Epithelix products have contributed to more than 1,200 scientific publications.
Epithelix’ Role in the MACRAMÉ Project
Epithelix contributes mainly in:
- Developing novel test methods based to test local tolerance of Advanced Materials on primary human airway epithelia.
- WP2 for the development and advancement of methods and protocols of local tolerance evaluation of characterized Advanced Materials . Primary cell based, advanced in vitro multicellular, air-liquid interface model, namely MucilAir™ reconstituted from bronchial region and AlveolAir™ reconstituted from alveolar region were used successfully with a high regulatory outlook potential (GIVIMP certification) are used for this purpose.
- WP4 for testing Advanced Materials on MucilAir™ and AlveolAir™ especially for Use Case 3: graphene in spray and Use Case 2: few layer graphene testing.
